Overexpression and mutation of EGFR leads to constitutive activation of the EGF/EGFR pathway, which is associated with increased tumor proliferation and chemotherapy resistance [27,28] and remains a major clinical challenge for cancer therapy. This evidence concerns the gene EGF and neoplasm.